# US 2020/0206361 A1 · Methods of treating mitochondrial disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0206361 A1
- Document ID: US20200206361A1
- Status: Published application
- Kind: A1
- Application number: 16/820,368
- Filed: 2020-03-16
- Published: 2020-07-02
- Earliest claimed: 2016-03-23
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Stephanie Cherqui
- Web page: https://patentgrep.com/patent/US20200206361A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/85: for animal cells
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2227/105: Murine
- A01K 2267/0318: Animal model for neurodegenerative disease, e.g. non- Alzheimer's
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Provided herein are methods for treating a disease or disorder associated with mitochondrial dysfunction through ex vivo introduction of a nucleic acid molecule into hematopoietic stem and progenitor cells (HSPCs) followed by transplantation of the HSPCs into a subject in need of treatment. The nucleic acid molecule may include a functional human frataxin (hFXN) or may include a gene editing system that when transfected into the cells removes a trinucleotide extension mutation of endogenous hFXN.

## Claims

### Claim 1

A method of treating a mitochondrial disease or disorder in a subject comprising contacting cells expressing hFXN from the subject with a vector encoding a gene editing system that when transfected into the cells removes a trinucleotide extension mutation of endogenous hFXN, thereby treating the mitochondrial disease or disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein the trinucleotide extension mutation is an expansion of GAA repeats in the first intron of hFXN.

### Claim 3 (depends on 1)

The method of claim 1, wherein the gene editing system is selected from the group consisting of CRISPR/Cas9, zinc finger nucleases, and transcription activator-life effector nucleases.

### Claim 4 (depends on 3)

The method of claim 3, wherein the gene editing system is CRISPR/Cas9.

### Claim 5 (depends on 4)

The method of claim 4, wherein the CRISPR/Cas9 system comprises one or more crRNA sequences selected from the group consisting of UP3 (SEQ ID NO: 17), UP4 (SEQ ID NO: 18), UP5 (SEQ ID NO: 19), DN3 (SEQ ID NO: 20), DN4 (SEQ ID NO: 21), and DN5 (SEQ ID NO: 22).

### Claim 6 (depends on 5)

The method of claim 5, wherein the CRISPR/Cas9 system comprises the crRNA sequences UP4 (SEQ ID NO: 18) and DN4 (SEQ ID NO: 21).

### Claim 7 (depends on 4)

The method of claim 4, wherein the CRISPR/Cas9 system comprises one or more guide target sequences selected from the group consisting of SEQ ID NOs: 91-95 and 96.

### Claim 8 (depends on 1)

The method of claim 1, wherein the step of contacting comprises administering to the subject an effective amount of the vector.

### Claim 9 (depends on 1)

The method of claim 1, wherein the step of contacting comprises obtaining a sample of cells from the subject, transfecting the gene editing system into the sample of cells, and thereafter, transplanting the transfected cells into the subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein the sample of cells is selected from the group consisting of blood cells and HSPCs.

### Claim 11 (depends on 10)

The method of claim 10, wherein the mitochondrial disease or disorder is selected from the group consisting of Friedreich's ataxia (FRDA), diabetes, Leigh syndrome, Leber's hereditary optic neuropathy, myoneurogenic gastrointestinal encephalopathy, and cancer.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 13 (depends on 12)

The method of claim 12, wherein the subject is human.

### Claim 14 (depends on 1)

The method of claim 1, wherein the vector is a viral vector selected from the group consisting of a lentiviral, adenoviral, and AAV vector.

### Claim 15 (depends on 9)

The method of claim 9, wherein the vector is pCCL-FRDAp-FXN or pCCL-EFS-FXN.

### Claim 16 (depends on 9)

The method of claim 9, wherein the transplantation corrects neurologic, cardiac and muscular complications within about 6-12 months post-transplantation.
